Pelthos Therapeutics Secures $30 Million Financing to Accelerate ZELSUVMI Commercialization
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy HRZN?
Source: Globenewswire
- Financing Support: Pelthos Therapeutics secured an initial $30 million financing from Horizon, with an additional $20 million available, aimed at accelerating the commercialization of its cutaneous infectious disease product portfolio, thereby enhancing financial flexibility and market competitiveness.
- Product Launch: The financing will expedite the launch of ZELSUVMI, the first FDA-approved treatment for molluscum that can be used at home, targeting patients and families struggling with this difficult-to-treat infection.
- Equity Dilution Control: This financing is non-dilutive, as Pelthos issued warrants for 65,488 shares, ensuring existing shareholders' interests are preserved while effectively managing the company's equity structure.
- Future Growth Potential: Pelthos plans to utilize the financing to support the launch of Xepi and Xeglyze, further expanding its market share in dermatological treatments to meet the increasing patient demand.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HRZN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HRZN
Wall Street analysts forecast HRZN stock price to rise
3 Analyst Rating
1 Buy
1 Hold
1 Sell
Hold
Current: 5.960
Low
6.00
Averages
6.67
High
7.50
Current: 5.960
Low
6.00
Averages
6.67
High
7.50
About HRZN
Horizon Technology Finance Corporation is a specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries. The Company's investment objective is to maximize its investment portfolio’s return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It is focused on making secured debt investments to venture capital and private equity-backed companies and publicly traded companies in its target industries. It seeks to invest in companies that vary by their stage of development, their target industries and sectors of target industries and their geographical location, as well as by the venture capital and private equity sponsors that support its portfolio companies. The Company’s adviser is Horizon Technology Finance Management LLC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Horizon Technology Finance to Announce Q4 Earnings on March 3rd
- Earnings Announcement Schedule: Horizon Technology Finance is set to release its Q4 2023 earnings report on March 3rd after market close, with consensus EPS estimated at $0.29 and revenue expected to reach $25.64 million, reflecting an 8.9% year-over-year growth, which will provide crucial insights into the company's financial health.
- Earnings Expectation Analysis: Over the past three months, Horizon's EPS estimates have seen no upward revisions and one downward revision, indicating a cautious market sentiment regarding its profitability, which could impact investor confidence and stock performance.
- Bond Issuance Details: Horizon recently priced an offering of $57.50 million in notes with a 7.00% interest rate due in 2028, a move that not only strengthens the company's capital structure but also provides funding for future investments.
- Market Rating Dynamics: Seeking Alpha's Quant Rating on Horizon Technology Finance reflects varying market perspectives on its future performance, prompting investors to monitor these rating changes to assess potential investment risks and opportunities.
See More
High Dividend Stocks Favored Amid Market Turbulence
- Investor Preference: During turbulent and uncertain market conditions, many investors are turning to high dividend-yielding stocks, which typically possess high free cash flows and reward shareholders with substantial dividends, thereby enhancing investor confidence.
- Analyst Ratings: Ratings from analysts for three high-yielding stocks in the financial sector, namely PennantPark Investment Corp., Horizon Technology Finance Corp., and Arbor Realty Trust Inc., indicate their strong investment appeal in the current market environment.
- Market Trends: As market instability intensifies, there is a growing interest among investors in companies that can provide stable cash flows, reflecting a heightened focus on risk management and potentially driving up the stock prices of these firms.
- Dividend Strategy: The allure of high dividend stocks lies in their ability to offer investors a continuous income stream, especially as economic uncertainties rise, which may attract more capital seeking safe investments.
See More
Horizon and Monroe Provide $40 Million Financing to OSSIO
- Financing Amount: Horizon Technology Finance Corporation and Monroe Capital LLC have closed an initial $40 million senior credit facility for Ossio Inc., with an additional $10 million available for future growth, reflecting strong confidence in OSSIO's development prospects.
- Market Positioning: OSSIO focuses on developing metal-free orthopedic fixation technology aimed at disrupting the multibillion-dollar global orthopedic market, indicating its innovative potential and market demand in the healthcare technology sector.
- Strategic Partnership: OSSIO's CEO Brian Verrier stated that this financing will accelerate their global expansion strategy, leveraging the expertise of Horizon and Monroe to enhance their impact in orthopedic medical technology.
- Industry Recognition: Monroe Capital expresses optimism about innovation in the Israeli life sciences sector, noting that OSSIO's metal-free bone regeneration solutions align closely with their technology finance strategy, signaling future growth opportunities.
See More
Horizon Technology Finance Provides $50 Million Loan Facility to Pelthos Therapeutics
- Financing Support: Horizon Technology Finance has provided a $50 million venture loan facility to Pelthos Therapeutics, with an initial funding of $30 million and up to $20 million for future growth, reflecting confidence in Pelthos' innovative products.
- Product Innovation: Pelthos' ZELSUVMI™ (berdazimer) topical gel has received FDA approval for treating molluscum contagiosum, offering a new at-home treatment option that could transform patient care approaches.
- Market Expansion: Pelthos has also acquired rights to Xepi® Cream and Xeglyze®, with the loan proceeds aimed at promoting these products, facilitating further expansion in the dermatology market.
- Strategic Partnership: Horizon's CIO Paul Seitz noted that this financing will assist Pelthos in promoting its products within pediatric and dermatologic communities, further driving business growth and showcasing Horizon's expertise in the life sciences sector.
See More
Horizon Technology Finance Corp Prices $57.5M Notes Offering with 19.61% Dividend Yield
- Attractive Dividend Yield: Horizon Technology Finance Corp offers a 19.61% dividend yield, showcasing its strong free cash flow and commitment to shareholder returns, which enhances market interest in its stock.
- Analyst Rating Changes: Maxim Group analyst Michael Diana maintained a Buy rating but lowered the price target from $10 to $7.5, reflecting a cautious outlook on future market performance despite a 56% accuracy rate.
- Financial Update: On December 11, 2025, Horizon Technology Finance priced a $57.5 million offering of 7.00% notes, which is expected to provide stable cash inflows to support future investments and operations.
- Market Reaction: Benzinga Pro's real-time news alerts investors to the latest developments regarding Horizon Technology Finance, indicating sustained market interest in high-yield stocks, especially amid economic uncertainty.
See More
Pelthos Therapeutics Secures $30 Million Financing to Accelerate ZELSUVMI Commercialization
- Financing Support: Pelthos Therapeutics secured an initial $30 million financing from Horizon, with an additional $20 million available, aimed at accelerating the commercialization of its cutaneous infectious disease product portfolio, thereby enhancing financial flexibility and market competitiveness.
- Product Launch: The financing will expedite the launch of ZELSUVMI, the first FDA-approved treatment for molluscum that can be used at home, targeting patients and families struggling with this difficult-to-treat infection.
- Equity Dilution Control: This financing is non-dilutive, as Pelthos issued warrants for 65,488 shares, ensuring existing shareholders' interests are preserved while effectively managing the company's equity structure.
- Future Growth Potential: Pelthos plans to utilize the financing to support the launch of Xepi and Xeglyze, further expanding its market share in dermatological treatments to meet the increasing patient demand.
See More
Horizon Technology Finance to Announce Q4 Earnings on March 3rd
- Earnings Announcement Schedule: Horizon Technology Finance is set to release its Q4 2023 earnings report on March 3rd after market close, with consensus EPS estimated at $0.29 and revenue expected to reach $25.64 million, reflecting an 8.9% year-over-year growth, which will provide crucial insights into the company's financial health.
- Earnings Expectation Analysis: Over the past three months, Horizon's EPS estimates have seen no upward revisions and one downward revision, indicating a cautious market sentiment regarding its profitability, which could impact investor confidence and stock performance.
- Bond Issuance Details: Horizon recently priced an offering of $57.50 million in notes with a 7.00% interest rate due in 2028, a move that not only strengthens the company's capital structure but also provides funding for future investments.
- Market Rating Dynamics: Seeking Alpha's Quant Rating on Horizon Technology Finance reflects varying market perspectives on its future performance, prompting investors to monitor these rating changes to assess potential investment risks and opportunities.
See More
High Dividend Stocks Favored Amid Market Turbulence
- Investor Preference: During turbulent and uncertain market conditions, many investors are turning to high dividend-yielding stocks, which typically possess high free cash flows and reward shareholders with substantial dividends, thereby enhancing investor confidence.
- Analyst Ratings: Ratings from analysts for three high-yielding stocks in the financial sector, namely PennantPark Investment Corp., Horizon Technology Finance Corp., and Arbor Realty Trust Inc., indicate their strong investment appeal in the current market environment.
- Market Trends: As market instability intensifies, there is a growing interest among investors in companies that can provide stable cash flows, reflecting a heightened focus on risk management and potentially driving up the stock prices of these firms.
- Dividend Strategy: The allure of high dividend stocks lies in their ability to offer investors a continuous income stream, especially as economic uncertainties rise, which may attract more capital seeking safe investments.
See More
Horizon and Monroe Provide $40 Million Financing to OSSIO
- Financing Amount: Horizon Technology Finance Corporation and Monroe Capital LLC have closed an initial $40 million senior credit facility for Ossio Inc., with an additional $10 million available for future growth, reflecting strong confidence in OSSIO's development prospects.
- Market Positioning: OSSIO focuses on developing metal-free orthopedic fixation technology aimed at disrupting the multibillion-dollar global orthopedic market, indicating its innovative potential and market demand in the healthcare technology sector.
- Strategic Partnership: OSSIO's CEO Brian Verrier stated that this financing will accelerate their global expansion strategy, leveraging the expertise of Horizon and Monroe to enhance their impact in orthopedic medical technology.
- Industry Recognition: Monroe Capital expresses optimism about innovation in the Israeli life sciences sector, noting that OSSIO's metal-free bone regeneration solutions align closely with their technology finance strategy, signaling future growth opportunities.
See More
Horizon Technology Finance Provides $50 Million Loan Facility to Pelthos Therapeutics
- Financing Support: Horizon Technology Finance has provided a $50 million venture loan facility to Pelthos Therapeutics, with an initial funding of $30 million and up to $20 million for future growth, reflecting confidence in Pelthos' innovative products.
- Product Innovation: Pelthos' ZELSUVMI™ (berdazimer) topical gel has received FDA approval for treating molluscum contagiosum, offering a new at-home treatment option that could transform patient care approaches.
- Market Expansion: Pelthos has also acquired rights to Xepi® Cream and Xeglyze®, with the loan proceeds aimed at promoting these products, facilitating further expansion in the dermatology market.
- Strategic Partnership: Horizon's CIO Paul Seitz noted that this financing will assist Pelthos in promoting its products within pediatric and dermatologic communities, further driving business growth and showcasing Horizon's expertise in the life sciences sector.
See More
Horizon Technology Finance Corp Prices $57.5M Notes Offering with 19.61% Dividend Yield
- Attractive Dividend Yield: Horizon Technology Finance Corp offers a 19.61% dividend yield, showcasing its strong free cash flow and commitment to shareholder returns, which enhances market interest in its stock.
- Analyst Rating Changes: Maxim Group analyst Michael Diana maintained a Buy rating but lowered the price target from $10 to $7.5, reflecting a cautious outlook on future market performance despite a 56% accuracy rate.
- Financial Update: On December 11, 2025, Horizon Technology Finance priced a $57.5 million offering of 7.00% notes, which is expected to provide stable cash inflows to support future investments and operations.
- Market Reaction: Benzinga Pro's real-time news alerts investors to the latest developments regarding Horizon Technology Finance, indicating sustained market interest in high-yield stocks, especially amid economic uncertainty.
See More
Pelthos Therapeutics Secures $30 Million Financing to Accelerate ZELSUVMI Commercialization
- Financing Support: Pelthos Therapeutics secured an initial $30 million financing from Horizon, with an additional $20 million available, aimed at accelerating the commercialization of its cutaneous infectious disease product portfolio, thereby enhancing financial flexibility and market competitiveness.
- Product Launch: The financing will expedite the launch of ZELSUVMI, the first FDA-approved treatment for molluscum that can be used at home, targeting patients and families struggling with this difficult-to-treat infection.
- Equity Dilution Control: This financing is non-dilutive, as Pelthos issued warrants for 65,488 shares, ensuring existing shareholders' interests are preserved while effectively managing the company's equity structure.
- Future Growth Potential: Pelthos plans to utilize the financing to support the launch of Xepi and Xeglyze, further expanding its market share in dermatological treatments to meet the increasing patient demand.
See More
